Vaccine · 2017 · 51 citations · 32 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyAdverse Events Following ImmunizationTuberculosis VaccinationVaccinationVaccine EffectivenessVaccine EfficacyVaccine SafetyAdult Tuberculosis VaccinationAntigen-specific T Cell ResponsesCd4 Positive T Cell ResponsesCd4+ T Helper Cell ResponsesFusion Protein VaccinesNew Tuberculosis VaccinesT-cell ImmunogenicityTuberculosis Vaccine Development
BACKGROUND: Novel vaccine strategies are required to provide protective immunity in tuberculosis (TB) and prevent development of active disease. We investigated the safety and immunogenicity of a novel TB vaccine candidate, H4:IC31 (AERAS-404) that is composed of a fusion protein of M. tuberculosis antigens Ag85B and TB10.4 combined with an IC31® adjuvant. METHODS: T cell responses. RESULTS: Th1 responses were most prominent after two doses of H4:IC31 containing 5, 15, or 50μg of H4 in combination with the 500nmol IC31 adjuvant dose. CONCLUSIONS: T cell responses in previously BCG-vaccinated healthy individuals. These dose-escalation trials provided evidence that the optimal antigen-adjuvant dose combinations are 5, 15, or 50μg of H4 and 500nmol of IC31. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02066428 and NCT02074956.
32
Graham A. Colditz, Catherine S. Berkey, Frederick Mosteller et al. · PEDIATRICS · 1995 · 692 citations
Marcus A. Horwitz, Günter Harth, Barbara Jane Dillon et al. · Proceedings of the National Academy of Sciences · 2000 · 435 citations · Full text